Canada· CA-DIN-02491087
EMGALITY
A galcanezumab product containing galcanezumab, registered in Canada by ELI LILLY CANADA INC. The same ATC class is registered in 13 of our 19 countries.
Checked against Health Canada Drug Product Database (Canada) on
Informational only — not a medical device.
Where it is registered
Galcanezumab is registered in 13 of 19 countries.
Countries holding a registration under ATC N02CD02 (galcanezumab), each read from that country’s own register.
- This record: Canada, from Health Canada Drug Product Database (Canada)
- 9 of them publish a price we can compare per daily dose
Galcanezumab · ATC N02CD02
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Health Canada Drug Product Database (Canada)- Active substance
- GALCANEZUMAB
- Manufacturer
- ELI LILLY CANADA INC
- Country
- Canada (CA)
- ATC code
- N02CD02
- ATC class
- Galcanezumab
- Defined daily dose
- 4 mg, P
- Reimbursed
- Not published by this register
- Source register
- Health Canada Drug Product Database (Canada)
- Last checked
- October 1, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Galcanezumab in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaEMGALITYEli Lilly Nederland B.V., Utrecht
- United StatesEMGALITYEli Lilly and Company
- SwitzerlandEmgality
- SpainEMGALITY 120 MG SOLUCION INYECTABLE EN JERINGA PRECARGADAEli Lilly Nederland B.V.
- FinlandEmgalityEli Lilly Nederland B.V.
- BelgiumEmgality 120 mgEli Lilly Nederland
- IcelandEmgalityEli Lilly Nederland B.V.*
- Japanガルカネズマブ（遺伝子組換え）日本イーライリリー
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Emgality
- Liechtenstein · Emgality
- Norway · Emgality
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Health Canada Drug Product Database (Canada). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/a7262b59-bb5c-4ce4-a556-2875c106d27b GET /v1/drugs/a7262b59-bb5c-4ce4-a556-2875c106d27b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"din": "02491087",
"form": "SOLUTION",
"class": "Human",
"routes": [
"SUBCUTANEOUS"
],
"source": "health_canada_dpd",
"status": "MARKETED",
"atc_raw": "N02CD02",
"schedule": [
"Prescription",
"Schedule D"
],
"drug_code": "98110",
"strengths": [
"120 MG"
],
"ahfs_class": null,
"substances": [
"GALCANEZUMAB"
],
"product_categorization": null
}See everything about galcanezumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.